---
title: "CADL.US (CADL.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CADL.US/news.md"
symbol: "CADL.US"
name: "CADL.US"
parent: "https://longbridge.com/en/quote/CADL.US.md"
datetime: "2026-05-21T00:35:15.035Z"
locales:
  - [en](https://longbridge.com/en/quote/CADL.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CADL.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CADL.US/news.md)
---

# CADL.US (CADL.US) — Related News

### [Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data](https://longbridge.com/en/news/287089067.md)
*2026-05-20T15:13:00.000Z*
> Candel Therapeutics (NASDAQ:CADL) is preparing to submit a biologics license application by year-end, following positive

### [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
*2026-05-16T18:47:05.000Z*
> Candel Therapeutics reported positive Phase 3 trial data for aglatimagene besadenovec in localized prostate cancer, show

### [Candel Therapeutics Highlights Phase 3 Prostate Cancer Data](https://longbridge.com/en/news/286620897.md)
*2026-05-15T22:08:28.000Z*
> Candel Therapeutics announced positive Phase 3 trial data for aglatimagene besadenovec in localized prostate cancer duri

### [Candel Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286417192.md)
*2026-05-14T12:32:59.000Z*
### [Candel Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286415130.md)
*2026-05-14T12:17:22.000Z*